We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Laboratory Automation System Installed to Increase Throughput Capacity for Large Clinical Trials

By LabMedica International staff writers
Posted on 18 Aug 2014
Print article
Automation will first be used to accelerate the testing of blood samples in an expanded colorectal cancer screening trial.

VolitionRx Ltd. (Namur, Belgium and Singapore), a company focused on developing blood-based diagnostic tests for different types of cancer, has installed a Tecan EVO200 automated liquid handling system in its Namur laboratory. The Tecan EVO200 is a robot that will significantly accelerate VolitionRx’s large-scale clinical studies by increasing the throughput and rate of blood sample analysis by up to 5 times that of the current manual methods.

Initially the robot will be used in a stand-alone mode but Volition is in the process of establishing a Laboratory Information Management System (LIMS) which will integrate the robot into a wider automation system. This will provide a workflow incorporating blood sample recognition, testing, data capture, and quality control as part of a quality management system.

VolitionRx also recently outsourced large-scale production of their NuQ kits to complement the increased sample processing capabilities the EVO200 system brings. Outsourced kit production and implementation of the quality system will be overseen by newly appointed Chief Operations Officer, Gaetan Michel. These are key milestones in moving towards European CE market approval and the ramp-up for the release of kits into the clinical setting.

Installation of the robot is particularly significant as the company has now increased by 3,000 (from 11,000 to 14,000) the number of prospective blood samples to be included in its on-going colorectal cancer clinical trial, jointly sponsored by VolitionRx and the University of Copenhagen. The study is designed to evaluate the validity of VolitionRx’s proprietary NuQ panel as a first-step screening tool for colorectal cancer and has been expanded by 42% since the study began. The additional blood samples are being collected by Prof. Hans Jørgen Nielsen, professor of surgical oncology at Hvidovre Hospital (University of Copenhagen), and collaborators at 7 additional Danish hospital departments.

Cameron Reynolds, CEO of VolitionRx, said, “This is an exciting time for Volition with lots of positive change as we move towards regulatory approval and clinical launch of our products. The automated sample testing technology we have invested in will speed up our workflow, and the extension to our trial with Hvidovre Hospital will give us the opportunity to analyze further data in relation to colonoscopy findings. The next key milestone will be the release of the first data from our pivotal Danish trials at the Aegis Capital Corp. 2014 Healthcare & Technology conference, to be held September 10–13, 2014, in Las Vegas, Nevada.”

Other clinical trials assessing the effectiveness of Volition’s assays include a 4,000-patient prospective study of patients with the 20 most prevalent cancers at University Hospital in Bonn (Germany) and a 250-patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital in Belgium.

Related Links:

VolitionRx


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.